Clinical trials: Alzheimer Disease, At Risk
Memory Disorders, Cognitive Impairment
Brain Boosters 2 in Persons at Risk for Alzheimer's Disease: a Digital Application Supported Intervention
The purpose of this research is to determine if training in memory support aids and healthy lifestyle activities (physical exercise, mentally stimulating activities and stress management) can have a positive effect on memory…
- Trial name
- BB2 (NCT05027789)
- Testing
- Self-Guided, Structured Group
- Where
- United States
- Volunteers
- 263 people
- Sponsor
- University of California, Davis
Alzheimer Disease
Study of Tau Imaging With the Use of [18F]MK-6240 Tracer
The recent development of a PET tracer,[18F]MK-6240(an[18F]tau imaging agent,CerveauTechnologies)that has high affinity for the human phosphorylated tau deposits in AD brain offers new opportunities to investigate tau pathology.
- Trial name
- MKADAD (NCT04104659)
- Testing
- MK 6240
- Where
- United States
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Tammie L. S. Benzinger, MD, PhD
Dementia, Alzheimer Disease
A Study to Evaluate the Efficacy and Safety of Galantamine in Patients With Mild Cognitive Impairment
The purpose of this study is to evaluate the efficacy and safety of galantamine treatment in patients with mild cognitive impairment.
- Trial name
- NCT00236574
- Testing
- Galantamine hydrobromide
- Volunteers
- 974 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Alzheimer Disease
Learning Amyloid and Tau Results
This is a prospective, single-cohort, single-center, observational study to assess if learning one's Alzheimer's disease biomarker test result impacts longitudinal psychosocial, behavioral, and neuropsychological outcomes, and to…
- Trial name
- NCT07222930
- Testing
- Disclose amyloid, tau results, Follow-up Assessments
- Where
- United States
- Volunteers
- 240 people, healthy volunteers welcome
- Sponsor
- University of Wisconsin, Madison
Alzheimers Disease
A Study of CNP520 Versus Placebo in Participants at Risk for the Onset of Clinical Symptoms of Alzheimer's Disease
The purpose of this study is to determine the effects of CNP520 on cognition, global clinical status, and underlying AD pathology, as well as the safety of CNP520, in people at risk for the onset of clinical symptoms of AD based…
- Trial name
- GS2 (NCT03131453)
- Testing
- CNP520 50mg, CNP520 15mg
- Where
- 194 sites in United States, Argentina and 23 more
- Volunteers
- 1,145 people, healthy volunteers welcome
- Sponsor
- Novartis Pharmaceuticals
Alzheimer's Disease
A Community-Based Screening Program to Identify Participants at High Risk for Amyloid Pathology
The primary purpose of this study is to identify participants with or without symptoms of Alzheimer's Disease (AD) that are at high risk for brain amyloid pathology using blood-based biomarkers.
- Trial name
- NCT06043700
- Testing
- No Intervention
- Where
- 3 sites in United States
- Volunteers
- 2,000 people, healthy volunteers welcome
- Sponsor
- Eisai Limited
Alzheimers Disease, Dementia
Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation. Master Protocol DIAN-TU-001
The purpose of this study is to assess the safety, tolerability, biomarker, cognitive and clinical efficacy of investigational products in participants with an Alzheimer's disease-causing mutation by determining if treatment with…
- Conditions
- Alzheimers Disease, Dementia, Alzheimers Disease, Familial
- Trial name
- DIAN-TU (NCT01760005)
- Testing
- Gantenerumab, Solanezumab, E2814
- Where
- 38 sites in United States, Argentina and 13 more
- Volunteers
- 490 people, healthy volunteers welcome
- Sponsor
- Washington University School of Medicine
Alzheimer's Disease, Plaque, Amyloid
Cognitive Health in Ageing Register: Investigational, Observational and Trial Studies in Dementia Research: Prospective Readiness Cohort Study
The purpose of this study is to prospectively investigate the longitudinal change of the components of the Preclinical Alzheimer Cognitive Composite (PACC) and the components (index scores) of the Repeatable Battery for the…
- Trial name
- CHARIOT:PRO (NCT02114372)
- Where
- 2 sites in United Kingdom
- Volunteers
- 1,136 people, healthy volunteers welcome
- Sponsor
- Janssen Research & Development, LLC
Alzheimer Disease
Targeting Default Mode Network Dysfunction in Persons At Risk of Alzheimer's Disease with Non-invasive Techniques
Default mode network (DMN) dysfunction is a well-established feature of Alzheimer's Disease (AD) and is already present in preclinical stages and in subjects at risk for AD, thus offering a potential target for early…
- Trial name
- NEST4AD (NCT05984446)
- Testing
- real-rTMS
- Where
- Italy
- Volunteers
- 86 people, healthy volunteers welcome
- Sponsor
- IRCCS Centro San Giovanni di Dio Fatebenefratelli
Alzheimer's Disease, Mild Cognitive Impairment
Cognition Platform Study in Participants at Risk for Alzheimer's Disease (AD) (MK-0000-413)
The main purpose of this study is to assess the ability of a repeated high-frequency site-based computerized cognitive assessment to evaluate the potential treatment effects of donepezil (MK-0000) compared with placebo among…
- Trial name
- NCT04730635
- Testing
- Donepezil
- Where
- 10 sites in United States, Australia
- Volunteers
- 44 people
- Sponsor
- Merck Sharp & Dohme LLC
Alzheimer Disease
Donanemab (LY3002813) Trial in Chinese Participants With Cognitively Unimpaired (Preclinical) Alzheimer's Disease
The main purpose of this study is to evaluate the effects of donanemab (LY3002813) versus placebo in Chinese participants who are at risk for decline of memory, language and physical ability to perform activities of daily living…
- Trial name
- NCT07571161
- Testing
- Donanemab
- Where
- 30 sites in China
- Volunteers
- 140 people
- Sponsor
- Eli Lilly and Company
Mild Cognitive Impairment, Alzheimer Dementia
Exercise, Brain, Cognition, OMICs, Molecular Markers and Functionality in People at Risk of Mild Cognitive Impairment
This project aims to examine the effect of a 5-month period supervised exercise intervention on brain, cognition, OMICs, Molecular Markers and functional status in older people at risk of mild cognitive impairment.
- Trial name
- NCT03923712
- Testing
- Supervised Exercise Programme
- Where
- Spain
- Volunteers
- 98 people
- Sponsor
- University of Cadiz
Alzheimers Disease
A Study to Evaluate the Efficacy and Safety of Gantenerumab in Participants at Risk for or at the Earliest Stages of Alzheimer's Disease (AD)
A study to evaluate the efficacy and safety of gantenerumab in amyloid-positive, cognitively unimpaired participants at risk for or at the earliest stages of AD.
- Trial name
- SKYLINE (NCT05256134)
- Testing
- Gantenerumab
- Where
- 63 sites in United States, Argentina and 8 more
- Volunteers
- 25 people
- Sponsor
- Hoffmann-La Roche
Alzheimer's Disease
Statin Effects on Beta-Amyloid and Cerebral Perfusion in Adults at Risk for Alzheimer's Disease
The purpose of the research is to see how simvastatin affects a substance in the body called beta-amyloid. Beta-amyloid is found in the brain and in the liquid around the brain and spinal cord.
- Trial name
- SHARP (NCT00939822)
- Testing
- Simvastatin
- Where
- United States
- Volunteers
- 88 people, healthy volunteers welcome
- Sponsor
- University of Wisconsin, Madison
Physical Inactivity
Intergenerational Behavioral Intervention to Enhance Physical Activity in Older Adults at Risk for Alzheimer's Disease
This is a four-week pilot randomized controlled trial of a behavioral intervention in older adults at risk for Alzheimer's disease. Older participants are a subgroup from the PREVENT-AD longitudinal cohort.
- Trial name
- HABS (NCT06038643)
- Testing
- Motivational behavioural intervention and daily activities monitoring, Active Control
- Where
- Canada
- Volunteers
- 76 people, healthy volunteers welcome
- Sponsor
- Douglas Mental Health University Institute
Alzheimer's Disease
A Study of Trontinemab in Cognitively Unimpaired Individuals at Risk for Progression to Symptomatic Alzheimer's Disease
This study will evaluate the efficacy and safety of trontinemab in participants with biomarker evidence of Alzheimer's Disease (AD) pathology but with no cognitive or functional impairment, who are at risk for progression to mild…
- Trial name
- PrevenTRON (NCT07717411)
- Testing
- Trontinemab
- Where
- 34 sites in United States, Argentina and 5 more
- Volunteers
- 1,600 people
- Sponsor
- Hoffmann-La Roche
Heart Failure NYHA Class II, Heart Failure NYHA Class III
Biomarker Study: Heart Failure Patients at Risk
In order to determine if NfL can be a prognostic biomarker for VCID, participants will undergo a baseline evaluation consisting of neuropsychological testing and a blood draw with a 12-month follow-up consisting of…
- Conditions
- Heart Failure NYHA Class II, Heart Failure NYHA Class III, Heart Failure NYHA Class IV
- Trial name
- NCT05336175
- Testing
- Angiotensin 1-7, Saline solution
- Where
- 2 sites in United States
- Volunteers
- 40 people
- Sponsor
- University of Arizona
Dementia Prevention, Subjective Cognitive Impairment
The Brain Health PRO Online Risk Factor Reduction Study to Prevent Dementia
This study will recruit participants at risk for dementia to participate in an online educational program called Brain Health PRO (BHPro).
- Conditions
- Dementia Prevention, Subjective Cognitive Impairment, Mild Cognitive Impairment, Cognitive Change
- Trial name
- BHPROOF (NCT07364019)
- Testing
- Brain Health PRO
- Where
- Canada
- Volunteers
- 700 people, healthy volunteers welcome
- Sponsor
- University of British Columbia
Healthy Aging, Risk Reduction
Validation of the REMINDER Dementia Risk Reduction Program
Until now, neuropsychological interventions aimed to optimize cognitive function and to have functional impact in individuals at risk of AD (MCI patients) were scarce in validity studies.
- Conditions
- Healthy Aging, Risk Reduction, Old Age; Dementia
- Trial name
- REMINDER (NCT05296980)
- Testing
- REMINDER, Brain health Psychoeducation
- Where
- Portugal
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- University of Coimbra
Alzheimer Disease, Dementia
Shanghai At Risk for Alzheimer's Disease: a Cohort Study
The goal of this cohort study is to estimate the incidence of AD in the first-degree relatives of patients with AD. The main questions it aims to answer are: cognitive changes of subjects at high risk of AD as ageing…
- Conditions
- Alzheimer Disease, Dementia, Neurodegenerative Diseases, Cognitive Impairment
- Trial name
- SHARAD (NCT05597410)
- Where
- China
- Volunteers
- 3,418 people, healthy volunteers welcome
- Sponsor
- Ruijin Hospital